Floatz logo

L-CYSTEINE, L-CYSTEINYL-L-ARGINYLGLYCYL-L-.ALPHA.-ASPARTYL-L-LYSYLGLYCYL-L-PROLYL-L-.ALPHA.-ASPARTYL-, CYCLIC (1->9)-DISULFIDE

Stage IV Breast Cancer

City of Hope Medical Centerprotein_peptidePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

225 Active assets in the Stage IV Breast Cancer cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 3BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB
TAMOXIFEN
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Trastuzumab Deruxtecan
SWOG Cancer Research Network
Phase 4BBB

View all 50 →

Same molecule, other indications

L-CYSTEINE, L-CYSTEINYL-L-ARGINYLGLYCYL-L-.ALPHA.-ASPARTYL-L-LYSYLGLYCYL-L-PROLYL-L-.ALPHA.-ASPARTYL-, CYCLIC (1->9)-DISULFIDE is also rated in:

pancreatic acinar cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →